Silver(I) Bromide Phosphines Induce Mitochondrial-Mediated Apoptosis in Malignant Human Colorectal Cells.

Due to its emerging resistance to current therapies, colon cancer remains one of the most difficult types of cancer to treat. Silver, a non-invasive metal, is well-known for its antimicrobial and anti-cancer properties. Two novel silver(I) phosphine complexes, [silver(I) diphenyl-2-pyridylphosphine]Br () and [silver(I) is 4-(dimethylamino)phenyldiphenylphosphine]Br (), were synthesized and characterized by elemental analysis, infrared spectroscopy, and nuclear magnetic resonance (H, C, P). To assess the complexes' potentials as antiproliferative agents, experiments were conducted on human colorectal cancer cells (HT-29) in vitro. The evaluation involved the analysis of morphological changes, the performance of an alamarBlue proliferation assay, and the undertaking of flow cytometric analyses to detect mitochondrial alterations. Complex displayed superior selectivity and significant inhibitory effects on malignant HT-29 cells while exhibiting minimal toxicity towards two non-malignant HEK-293 and MRHF cells. Moreover, after 24 h of treatment, complex (IC, 7.49 µM) demonstrated higher efficacy in inhibiting cell proliferation compared with complex (IC, 21.75 µM) and CDDP (IC, 200.96 µM). Flow cytometric studies indicated that complex induced regulated cell death, likely through mitochondrial-mediated apoptosis. Treatment with complex induced morphological changes indicative of apoptosis, which includes membrane blebbing, PS externalization, increased levels of reactive oxygen species (ROS) and mitochondrial membrane depolarization (ΔΨm). These observations suggest that complex targets the mitochondria and holds promise as a novel metal-based anti-cancer therapeutic for the selective treatment of colorectal cancer.